Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Analyst ; 149(3): 614-637, 2024 Jan 29.
Article in English | MEDLINE | ID: mdl-38083968

ABSTRACT

Numerous innovative nanoparticle formulations of drugs and biologics, named nano-formulations, have been developed in the last two decades. However, methods for their scaled-up production are still lagging, as the amount needed for large animal tests and clinical trials is typically orders of magnitude larger. This manufacturing challenge poses a critical barrier to successfully translating various nano-formulations. This review focuses on how microfluidics technology has become a powerful tool to overcome this challenge by synthesizing various nano-formulations with improved particle properties and product purity in large quantities. This microfluidic-based manufacturing is enabled by microfluidic mixing, which is capable of the precise and continuous control of the synthesis of nano-formulations. We further discuss the specific applications of hydrodynamic flow focusing, a staggered herringbone micromixer, a T-junction mixer, a micro-droplet generator, and a glass capillary on various types of nano-formulations of polymeric, lipid, inorganic, and nanocrystals. Various separation and purification microfluidic methods to enhance the product purity are reviewed, including acoustofluidics, hydrodynamics, and dielectrophoresis. We further discuss the challenges of microfluidics being used by broader research and industrial communities. We also provide future outlooks of its enormous potential as a decentralized approach for manufacturing nano-formulations.


Subject(s)
Biological Products , Nanoparticles , Animals , Microfluidics/methods , Polymers , Nanoparticles/chemistry , Glass
2.
Mol Pharm ; 10(6): 2167-75, 2013 Jun 03.
Article in English | MEDLINE | ID: mdl-23461341

ABSTRACT

The importance and advantages of three-dimensional (3D) cell cultures have been well-recognized. Tumor cells cultured in a 3D culture system as multicellular tumor spheroids (MTS) can bridge the gap between in vitro and in vivo anticancer drug evaluations. An in vitro 3D tumor model capable of providing close predictions of in vivo drug efficacy will enhance our understanding, design, and development of better drug delivery systems. Here, we developed an in vitro 3D tumor model by adapting the hydrogel template strategy to culture uniformly sized spheroids in a hydrogel scaffold containing microwells. The in vitro 3D tumor model was to closely simulate an in vivo solid tumor and its microenvironment for evaluation of anticancer drug delivery systems. MTS cultured in the hydrogel scaffold are used to examine the effect of culture conditions on the drug responses. Free MTS released from the scaffold are transferred to a microfluidic channel to simulate a dynamic in vivo microenvironment. The in vitro 3D tumor model that mimics biologically relevant parameters of in vivo microenvironments such as cell-cell and cell-ECM interactions, and a dynamic environment would be a valuable device to examine efficiency of anticancer drug and targeting specificity. These models have potential to provide in vivo correlated information to improve and optimize drug delivery systems for an effective chemotherapy.


Subject(s)
Antineoplastic Agents/pharmacology , Microfluidic Analytical Techniques/methods , Neoplasms/pathology , Spheroids, Cellular/drug effects , Cell Line, Tumor , Humans , Hydrogel, Polyethylene Glycol Dimethacrylate/chemistry , Microscopy, Electron, Scanning
3.
J Control Release ; 155(2): 289-95, 2011 Oct 30.
Article in English | MEDLINE | ID: mdl-21843562

ABSTRACT

Cystic fibrosis (CF) sputum, a tenacious biopolymer network accumulating in the airways, critically interferes with the effectiveness of pulmonary gene delivery. To overcome this challenge, nanoparticulate ternary gene-polymer complexes were encapsulated in inhalable dry microparticles containing mannitol. When applied on a layer of artificial sputum, which comprised major components of CF sputum such as DNA and mucin, mannitol microparticles rapidly dissolved in it and enhanced transport of nanoparticles across the sputum layer. Despite the improvement of nanoparticle transport in the artificial sputum, the gene-polymer complex passing the sputum did not show gene transfection because of the significant inactivation by DNA and, to a lesser extent, mucin. Particle size measurement suggested that aggregation of the gene transfer agents was mainly responsible for the activity loss. These results indicate that the delivery of gene transfer agent across CF sputum depended not only on the ability to penetrate the sputum but also on preservation of the activity during and/or after the transport.


Subject(s)
Cystic Fibrosis/therapy , Drug Carriers/chemistry , Gene Transfer Techniques , Lung/metabolism , Mannitol/chemistry , Nanoparticles/chemistry , Administration, Inhalation , Animals , Cross-Linking Reagents/chemistry , Cystic Fibrosis/genetics , DNA/administration & dosage , DNA/genetics , Drug Compounding , Hyaluronic Acid/chemistry , Mice , NIH 3T3 Cells , Particle Size , Polyethyleneimine/chemistry , Sputum/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL